Nexmezol (Esomeprazole)

Esomeprazole, the active ingredient in Nexmezol, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid secretion and is prescribed for conditions such as gastro‑oesophageal reflux disease, erosive esophagitis, peptic ulcer disease and as part of Helicobacter pylori eradication regimens.

GNH USA supplies Nexmezol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nexmezol (esomeprazole) is used to manage acid‑related disorders by decreasing gastric acid production. - Gastro‑oesophageal reflux disease (GERD): provides symptomatic relief of heartburn and promotes healing of esophageal irritation. - Erosive esophagitis: facilitates mucosal healing and prevents disease progression. - Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence. - Helicobacter pylori eradication: used in combination therapy to improve bacterial clearance.

Adverse reactions may occur with any medication and should be monitored by a healthcare professional.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhea: loose stools occurring intermittently. - Nausea: feeling of stomach upset. - Abdominal pain: discomfort in the upper abdomen.

Serious or Rare Side Effects: - Clostridioides difficile infection: severe colitis requiring medical attention. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Low serum magnesium: may cause muscle cramps or cardiac arrhythmia.

Before initiating therapy, consider the following safety measures. - Renal function assessment: adjust use in patients with severe impairment. - Hepatic disease evaluation: use cautiously in liver dysfunction. - Known hypersensitivity: avoid if allergic to esomeprazole or other PPIs. - Long‑term therapy monitoring: check magnesium levels periodically. - Store at ambient temperature: keep in the original pack, protect from moisture.

Esomeprazole can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect. - Atazanavir: decreased absorption and efficacy. - HIV protease inhibitors (e.g., ritonavir): increased esomeprazole exposure.

Moderate Interactions (Monitor Closely): - Digoxin: higher serum concentrations may occur. - Methotrexate: reduced clearance leading to toxicity. - Phenytoin: decreased plasma levels, possible loss of seizure control.